Skip to content
Screener

Free cash flow margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
23.3%-7.3pp
Gilead Sciences logo
Gilead SciencesGILD
42.5%+10.0pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-212%-95.8pp
Incyte logo
IncyteINCY
34%+12.3pp
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-586%-123pp

Other financials

Income statement

See full
Revenue$99.3M+65.7%
Gross profit$55.7M+403%
Operating income-$51.9M+54.4%
Net income-$47.3M+57.6%
EPS (diluted)-$0.11+66.7%

Balance sheet

See full
Cash & equivalents$110.8M-16.4%
Total debt$46.0M-11.8%
Total equity$736.0M+5.4%
Total assets$915.5M+0.9%

Cash flow

See full
Operating cash flow-$60.8M+9.8%
CapEx$5.4M-27.1%
Free cash flow-$66.3M+11.5%

Valuation

See full
Market cap$2.77B+222%
Enterprise value$2.71B+247%
P/S8.5×+5.0×

Profitability

See full
Gross margin48.4%+15.0pp
Operating margin-92.7%-29.0pp
Net margin-89.1%-27.6pp

Returns & leverage

See full
Return on equity-40.4%-7.8pp
Debt / equity0.1×0.0×
Current ratio4.3×+1.1×

Where this comes from

Calculated from Iovance Biotherapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 9:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091716

FAQ

What is Iovance Biotherapeutics, Inc.'s free cash flow margin?
Iovance Biotherapeutics, Inc. (IOVA) reported free cash flow margin of -91.2% in Q2 2026.
How has Iovance Biotherapeutics, Inc.'s free cash flow margin changed year-over-year?
Iovance Biotherapeutics, Inc.'s free cash flow margin increased by 31.9% year-over-year, from -134% to -91.2%.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s free cash flow margin?
Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s free cash flow margin has grown at a -93.7% compound annual growth rate (CAGR), from -32,305.3% to -127.6%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.

Ask your AI about Iovance Biotherapeutics, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude